Alife, which uses artificial intelligence to advance IVF, raises $22M

Today, 1 in 8 couples struggle with infertility, and the treatment options they have access to are both expensive, as well as inaccessible: according to the National Conference of State Legislatures, in-vitro fertilization cycles can cost anywhere from $12,000 to $17,000, and that doesn't include medication; when medication is added in, the cost can be double to around $25,000. And many patients don't just go through one cycle, but three to five cycles on average in order to have a successful pregnancy In order to help break through all of these difficulties, inefficiencies, and barriers to access, Alife Health, which announced a $22 million Series A round of funding on Tuesday, is trying a new approach: artificial intelligence. "We believe AI has tremendous potential to impact the effectiveness and equity of fertility care," said Paxton Maeder-York, Alife's CEO and founder. "Our team has worked tirelessly to construct one of the largest and most diverse IVF datasets from top fertility clinics around the world." The company's AI uses pattern recognition to analyze this data and determine correlations between treatments and positive outcomes.